Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The management of pregnancy in Gaucher disease.
Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A. Granovsky-Grisaru S, et al. Among authors: vom dahl s. Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):3-8. doi: 10.1016/j.ejogrb.2010.12.024. Epub 2011 Jan 26. Eur J Obstet Gynecol Reprod Biol. 2011. PMID: 21269752 Review.
The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S. Zimran A, et al. Among authors: vom dahl s. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):264-88. doi: 10.1016/j.bcmd.2009.04.003. Epub 2009 Jun 6. Blood Cells Mol Dis. 2009. PMID: 19502088 Review.
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM. Hollak CE, et al. Among authors: vom dahl s. Blood Cells Mol Dis. 2010 Jan 15;44(1):41-7. doi: 10.1016/j.bcmd.2009.09.006. Epub 2009 Oct 4. Blood Cells Mol Dis. 2010. PMID: 19804996
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD. Hollak CE, et al. Among authors: vom dahl s. Br J Haematol. 2012 Aug;158(4):528-38. doi: 10.1111/j.1365-2141.2012.09175.x. Epub 2012 May 29. Br J Haematol. 2012. PMID: 22640238 Free article.
Understanding the natural history of Gaucher disease.
Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Mistry PK, et al. Among authors: vom dahl s. Am J Hematol. 2015 Jul;90 Suppl 1:S6-11. doi: 10.1002/ajh.24055. Am J Hematol. 2015. PMID: 26096746 Free article. Review.
Hepatocellular carcinoma in Gaucher disease: an international case series.
Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Regenboog M, et al. Among authors: vom dahl s. J Inherit Metab Dis. 2018 Sep;41(5):819-827. doi: 10.1007/s10545-018-0142-y. Epub 2018 Feb 8. J Inherit Metab Dis. 2018. PMID: 29423829 Free PMC article.
Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.
Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A. Mehta A, et al. Among authors: vom dahl s. Intern Med J. 2019 May;49(5):578-591. doi: 10.1111/imj.14156. Intern Med J. 2019. PMID: 30414226 Free PMC article. Review.
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A; Advisory Council to the European Working Group on Gaucher Disease. Cox TM, et al. Among authors: vom dahl s. J Inherit Metab Dis. 2003;26(6):513-26. doi: 10.1023/a:1025902113005. J Inherit Metab Dis. 2003. PMID: 14605497 Review.
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.
Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM. Biegstraaten M, et al. Among authors: vom dahl s. Blood Cells Mol Dis. 2018 Feb;68:203-208. doi: 10.1016/j.bcmd.2016.10.008. Epub 2016 Oct 24. Blood Cells Mol Dis. 2018. PMID: 28274788 Free article.
122 results